

ACADEMIC DEBATE

AMERICAN LIVER FOUNDATION
NOVEMBER 30, 2006

The Mission of Transplant Professionals

To save lives and enhance the quality of life of patients with end stage organ failure.

To identify patients that will benefit from organ transplantation

To maximize the utilization of organs to benefit the maximum people

Should we use marginal donors for otherwise good risk patients with HCC beyond Milan criteria

Is the Milan criteria imperfect?

Should we transplant patients who have less optimal prognoses?

Can we transplant patients without affecting current organ allocation and utilization?

Studies that challenge the Milan Criteria

Author	Year	allograft	patients	Milan criteria total survival	free survival	Extended Milan criteria total survival	free survival
Todo	2004	DLIT	316	82	79.4	74.5	60
Kneteman	2004	OLT	40	94	81	90.5	76.8
Yao	2001	OLT	70	91.5	72.4	82.4	74.1

Is the Milan criteria imperfect? **YES**

Should we transplant patients who have less optimal prognoses?

Can we transplant patients without affecting current organ allocation and utilization?

Prognosis beyond Milan Criteria is not as good




FIGURE 3. Patient- and recurrence-free survival by the Milan criteria. From: Todo. Ann Surg. Volume 240(3). September 2004:451-461

Prognosis for HCC is grave without liver transplantation




Figure 1. Overall survival of patients entered into the protocol based on eventual transplant or removal from protocol ($P < .0001$). From: Roberts. Ann Surg. Volume 235(4). April 2002:532-539

Outcomes for Bone Marrow Transplant

HCC is the best place to start with Marginal Donors

- Transplant procedure is less complicated since patients are usually not ravaged by their liver disease
- Low incidence of extrahepatic manifestations of liver failure such as hepato-renal syndrome

Is the Milan criteria imperfect? **YES**

Should we transplant patients who have less optimal prognoses? **YES**

Can we transplant patients without affecting current organ allocation and utilization?

How do we transplant patients beyond the Milan Criteria without affecting current allocation?

Utilize Organs Currently Being discarded

2005

- 6120 liver transplants from cadaveric donors
- 570** hepatic allografts were procured and not utilized

2006 – (Jan-July)

- 3771 liver transplants from cadaveric donors
- 351** hepatic allografts were procured and not utilized

(projection: 600 discarded hepatic allografts for 2006)

www.unos.org (October '16, 2006)

Marginal donors

- Age (>55 years old)
- Hypotension prior to donation
 - Use of vasoactive drugs, dopamine
- Laboratory:
 - Serum sodium > 150 mEq/L
 - Bilirubin > 2mg/dL
 - ALT > 150 UI/L
- Viral infections: HCV+, HBV+, HIV+
- History of drug or alcohol abuse
- Micro or macro-steatosis

Will These Discarded Organs Work? YES

- Allografts from HCV+
 - Excellent results when both donor and recipient are HCV+
 - Excellent results with de novo HCV+ infection
- Allografts from HBSAg+
 - Preferentially allocated to anti-HBs+ or HBSag+ patients
 - De novo HBV infection appears benign and new anti-virals are extremely promising
- Allografts from HIV positive donors-HIV infection after LTX can be controlled
- Marginal grafts (by age, lab criteria, or clinical course prior to donation) with careful selection have been shown to work as well as "ideal" grafts

Will These Discarded Allograft Work

- Assume 600 hepatic allografts will be discarded this year
- If a minimum of 10% are utilized then 60 patients can be transplanted a year (300/5 years) from discarded allografts alone

Is the Milan criteria imperfect? YES

- Should we transplant patients who have less optimal prognoses? **YES**
- Can we transplant patients without affecting current organ allocation and utilization? **YES**

Proposed Scheme for
Allocation of Discarded Hepatic
Allografts

- Five-year multi-center trial
- Patients breach the Milan criteria
- Evaluate
 - Patient survival
 - Graft survival
 - Various types of neo-adjuvant chemotherapy

He is the best physician who is the
most ingenious Inspirer of hope.

Samuel Taylor Coleridge